Kyowa Kirin Co Ltd
TSE:4151

Watchlist Manager
Kyowa Kirin Co Ltd Logo
Kyowa Kirin Co Ltd
TSE:4151
Watchlist
Price: 2 523 JPY -0.86% Market Closed
Market Cap: 1.3T JPY
Have any thoughts about
Kyowa Kirin Co Ltd?
Write Note

Operating Margin
Kyowa Kirin Co Ltd

20.1%
Current
18%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
20.1%
=
Operating Profit
100.3B
/
Revenue
499B

Operating Margin Across Competitors

Country JP
Market Cap 1.3T JPY
Operating Margin
20%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 710.5B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Country US
Market Cap 373.5B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 202.7B CHF
Operating Margin
32%
Country CH
Market Cap 183.3B CHF
Operating Margin
31%
Country UK
Market Cap 162.4B GBP
Operating Margin
21%
Country IE
Market Cap 146B USD
Operating Margin
11%
No Stocks Found

Kyowa Kirin Co Ltd
Glance View

Market Cap
1.3T JPY
Industry
Pharmaceuticals

Kyowa Kirin Co., Ltd. is a global biopharmaceutical company rooted in Japan, well-regarded for its commitment to developing innovative therapies that address unmet medical needs. Founded in 1949, the company has evolved significantly over the decades, transitioning from a traditional pharmaceutical manufacturer to a cutting-edge biotechnology leader. Kyowa Kirin harnesses its expertise in research and development to focus on critical areas such as oncology, immunology, and nephrology, leveraging proprietary technologies to create unique biologics that enhance patient outcomes. With a diverse pipeline of products and a strong emphasis on collaboration, both within Japan and with international partners, the company positions itself as a key player in the rapidly evolving biopharmaceutical landscape. For investors, Kyowa Kirin represents not just a robust financial opportunity but also the embodiment of long-term value creation, reflecting the investment principles of renowned thinkers like Warren Buffett and Charlie Munger. The company maintains a sound financial profile, characterized by steady revenue growth, a solid balance sheet, and a commitment to shareholder returns through dividends and strategic reinvestments. As the global demand for innovative healthcare solutions escalates, Kyowa Kirin's ongoing commitment to R&D, coupled with its strategic alliances and acquisitions, positions it well for sustainable growth and resilience in the face of market fluctuations. Investors seeking to capitalize on the burgeoning biopharmaceutical sector should consider Kyowa Kirin as a potential long-term investment opportunity in a company poised to make a meaningful impact on global health.

Intrinsic Value
3 756.45 JPY
Undervaluation 33%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
20.1%
=
Operating Profit
100.3B
/
Revenue
499B
What is the Operating Margin of Kyowa Kirin Co Ltd?

Based on Kyowa Kirin Co Ltd's most recent financial statements, the company has Operating Margin of 20.1%.